While it may accelerate sputum and culture conversion in difficult TB cases, variability across trials and the potential for IFN-γ to cause tissue damage at high bacterial loads argue for careful dosing, inhaled administration, and guided patient selection using molecular biomarkers. This evidence concerns the gene IFNG and tuberculosis.